Weiss Multi-Strategy Advisers’s Elanco Animal Health ELAN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-505,815
Closed -$7.54M 156
2023
Q4
$7.54M Buy
505,815
+82,948
+20% +$940K 0.18% 148
2023
Q3
$4.75M Buy
+422,867
New +$4.91M 0.11% 241
2023
Q1
Sell
-217,455
Closed -$2.66M 657
2022
Q4
$2.66M Buy
+217,455
New +$2.71M 0.08% 340
2022
Q2
Sell
-28,025
Closed -$731K 694
2022
Q1
$731K Buy
+28,025
New +$746K 0.02% 536
2021
Q1
Sell
-94,896
Closed -$2.91M 738
2020
Q4
$2.91M Buy
+94,896
New +$2.9M 0.06% 349
2020
Q3
Sell
-1,380,118
Closed -$29.6M 589
2020
Q2
$29.6M Buy
+1,380,118
New +$30.5M 0.85% 19
2020
Q1
Sell
-263,971
Closed -$7.77M 475
2019
Q4
$7.77M Buy
263,971
+109,099
+70% +$2.96M 0.13% 228
2019
Q3
$4.12M Buy
154,872
+34,872
+29% +$1.05M 0.08% 285
2019
Q2
$4.06M Buy
+120,000
New +$3.9M 0.11% 194
2018
Q4
Sell
-110,000
Closed -$3.84M 494
2018
Q3
$3.84M Buy
+110,000
New +$3.87M 0.1% 246

Other funds holding ELAN

Weiss Multi-Strategy Advisers's ELAN Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Elanco Animal Health (ELAN) in Q1 2024, closing a stake of 505,815 shares — an estimated $7.54M sold.

Weiss Multi-Strategy Advisers first reported a position in ELAN in Q3 2018 and held it in 10 quarters. The position peaked at $29.6M in Q2 2020. 374 funds tracked by Wall St. Rank hold ELAN as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining Elanco Animal Health position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 505,815 Elanco Animal Health shares in Q1 2024, an estimated $7.54M.
  • Weiss Multi-Strategy Advisers first reported a position in Elanco Animal Health in Q3 2018 and held it in 10 quarters.
  • Weiss Multi-Strategy Advisers's Elanco Animal Health position peaked at $29.6M in Q2 2020.
  • 374 funds tracked by Wall St. Rank held Elanco Animal Health as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.